Alzheimer’s Drug Assessment In U.K. Will Turn To Select Populations
This article was originally published in The Pink Sheet Daily
Executive Summary
Comments from stakeholders prompt National Institute for Clinical Excellence request for additional evidence on clinical efficacy of memantine and acetylcholinesterase inhibitors in specific patient populations. Preliminary cost effectiveness appraisal had recommended against use of the Alzheimer’s drugs.
You may also be interested in...
Alzheimer’s Drugs Should Be Limited To Moderate Disease, U.K.’s NICE Says
National Institute for Health & Clinical Excellence recommends limited use of acetylcholinesterase inhibitors, finds against Namenda.
Alzheimer’s Drugs Should Be Limited To Moderate Disease, U.K.’s NICE Says
National Institute for Health & Clinical Excellence recommends limited use of acetylcholinesterase inhibitors, finds against Namenda.
Memantine Use Should Be Restricted, U.K. Cost-Effectiveness Group Says
National Institute for Clinical Excellence recommends against using Lundbeck’s Ebixa (Forest’s Namenda in the U.S.) for treating moderately severe to severe Alzheimer’s disease. Group also recommends against use of acetylcholinesterase inhibitors for mild to moderate Alzheimer’s.